Shatsky, Rebecca A.
Batra-Sharma, Hemali
Helsten, Teresa
Schwab, Richard B.
Pittman, Emily I.
Pu, Minya
Weihe, Elizabeth
Ghia, Emanuela M.
Rassenti, Laura Z.
Molinolo, Alfredo
Cabrera, Betty
Breitmeyer, James B.
Widhopf, George F. II
Messer, Karen
Jamieson, Catriona
Kipps, Thomas J.
Parker, Barbara A.
Funding for this research was provided by:
Pedal the Cause Moores Cancer Center
Oncternal Therapeutics, Inc.
Sanford Stem Cell Institute
California Institute for Regenerative Medicine (CIRM INFR4-13597, CIRM INFR4-13597)
April Krueger Women's Health Initiative
Curebound
National Cancer Institute United States (1U01AA029019)
Gonick Breast Cancer Research Fund
Breast Cancer Personalized Treatment Research Fund
Article History
Received: 27 October 2023
Accepted: 9 February 2024
First Online: 26 February 2024
Change Date: 13 March 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13058-024-01805-w
Declarations
:
: The study protocol was approved by the Human Research Protections Program (HRPP) at the University of California, San Diego (IRB #160178, NCT02776917).
: We obtained written informed consent from each patient prior to study enrollment. Consent for study participation included consent for publication of the data obtained from this study.
: R.A.S: Astra Zeneca (advisory board), Gilead (speaker’s bureau), Quantum Leap (consultant), Stemline (advisory board). Institutional Funding from OBI Pharmaceuticals, Quantum Leap, Astra Zeneca, and Gilead. ORCID profile: 0000-0003-2289-6234. H.B.S.: MJH Life Sciences (consultant). ORCID profile: 0009-0003-8700-1451. T.H.: No conflicts of interest. R.B.S.: Genentech, Inc. (current employee). Dr. Schwab was affiliated with the University of California San Diego Department of Medicine and Moores Cancer Center at the time this trial was conducted. ORCID profile: 0000-0002-0488-1226. E.I.P.: No conflicts of interest. M.P.: No conflicts of interest. E.W.: No conflicts of interest. E.M.G.: No conflicts of interest. ORCID profile: 0000-0002-6060-6106. L.Z.R.: No conflicts of interest. A.M.: No conflicts of interest. B.C.: No conflicts of interest. J.B.B.: Oncternal Therapeutics, Inc. (employee, Board director, stock owner, stock option holder). G.F.W. II: No conflicts of interest. K.M.: No conflicts of interest. C.J.: Dr. Jamieson is a co-founder of Aspera Biomedicines and receives royalties from Stanford University for patents related to Forty Seven, Inc. T.J.K.: Zilovertamab was developed by T.J.K. and his laboratory and licensed by the University of California to Oncternal Therapeutics, Inc. and VelosBio, Inc. which provided stock and research funding. ORCID profile: 0000-0002-0064-4549. B.A.P.: Dr. Barbara Parker has stock from Merck and Bioatla (spouse), consulting role with Bioatla (spouse), Samumed LLC (spouse), and Dare Biosciences, research funding to her institution from Glaxo/SmithKline, Genentech/Roche, Novartis, Pfizer, and Oncternal Therapeutics and receives royalties from Salk Institute (spouse). ORCID profile: 000-0003-0499-1289.